Mouse Sertoli Cells Inhibit Humoral-Based Immunity

Area of Science:

• Immunology
• Transplantation Biology
• Cell Biology

Background:

• Grafted tissue rejection is a major challenge in transplantation, often necessitating toxic immunosuppressants.
• Humoral immune responses, involving antibodies and complement, are critical drivers of graft rejection.
• Sertoli cells (SCs), known for their immunoregulatory properties, exhibit remarkable survival post-transplantation without immunosuppression.

Purpose of the Study:

• To investigate the role of Sertoli cells in regulating humoral immune factors, specifically complement and antibodies.
• To elucidate the mechanisms by which Sertoli cells evade immune-mediated rejection.

Main Methods:

• In vitro studies using mouse Sertoli cells exposed to human complement.
• In vivo transplantation of mouse Sertoli cells as allografts.
• Microarray analysis and ELISA to identify expressed complement inhibitory proteins.

Main Results:

• Mouse Sertoli cells demonstrated resistance to complement-mediated killing in vitro and survived in vivo with minimal antibody or complement deposition.
• At least 14 complement inhibitory proteins were identified in mouse Sertoli cells, inhibiting complement at multiple stages.
• A Sertoli cell line (MSC-1), despite eventual rejection, also showed complement resistance and inhibitor expression.

Conclusions:

• Sertoli cell-mediated inhibition of complement is a significant factor in their immune privilege and graft survival.
• While complement inhibition is crucial, other immune modulatory mechanisms likely contribute to Sertoli cell graft longevity.
• Elucidating these mechanisms could lead to improved strategies for enhancing transplant graft survival.